Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

https://www.sunpharma.com/

Latest From Sun Pharmaceutical Industries Ltd.

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

Six Glocal Trends That Could Lift Or Drift India Pharma In 2021

Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.

India Commercial

2021 Deal Action In India: Watch Private Equity And E-Pharmacy

Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.

Deals M & A

Upbeat On Injectables, Aurobindo Is Hiking Capacities

Aurobindo expects revenues from injectables to increase to $650m-$700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets, though big-ticket M&A is ruled out.

Strategy Manufacturing
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aditya Acquisition Company ltd
    • Caraco Pharmaceutical Laboratories, Ltd.
    • DUSA Pharmaceuticals, Inc.
    • InSite Vision, Inc.
    • JSC Biosintez
    • Ocular Technologies
    • Pola Pharma Inc.
    • Ranbaxy Laboratories Limited
    • Ranbaxy Solus
    • Solus Care
    • Sun Ophthalmics
    • Sun Pharma Global FZE
UsernamePublicRestriction

Register